Tretinoin Boosts Minoxidil Response via Enzymes

Key Takeaways

This study investigated whether topical tretinoin (all-trans retinoic acid, a retinoid) could increase the activity of sulfotransferase enzymes in hair follicles, the enzymes responsible for converting minoxidil into its active form, minoxidil sulfate. Twenty androgenetic alopecia patients (10 male, 10 female) applied 0.1% tretinoin cream to a marked scalp area for five days. Before and after treatment, researchers measured follicular sulfotransferase activity using the Minoxidil Response Test.

Among subjects initially predicted to be non-responders to minoxidil (7 out of 20), tretinoin significantly increased enzyme activity (p=0.0397), and 43% of those non-responders crossed the threshold into predicted responder status. For the group as a whole, the change was not statistically significant. The study was small, short-term, and measured only enzyme activity rather than actual hair regrowth. Still, it offers a compelling biochemical explanation for why tretinoin may improve minoxidil outcomes and opens the door to combination topical treatments.

Context and Purpose

Topical minoxidil remains the only US FDA-approved topical drug for androgenetic alopecia, yet fewer than 40% of patients see a meaningful clinical response. That is a frustrating statistic for anyone who has faithfully applied the solution morning and night for months without visible results.

The reason for this low response rate lies in biochemistry. Minoxidil itself is not the molecule that stimulates hair growth. It must first be converted, or “sulfonated,” into minoxidil sulfate by sulfotransferase enzymes present in the outer root sheath of the hair follicle. People whose follicles express low levels of these enzymes simply cannot activate the drug, and minoxidil passes through their scalp without doing much of anything.

For years, dermatologists have observed that adding tretinoin to a minoxidil regimen seems to improve results. The prevailing theory was that tretinoin thins the stratum corneum, the outermost skin barrier, allowing more minoxidil to penetrate. But that explanation never quite fit, because retinoids are actually known to increase dermal thickness, not reduce it. This study set out to test a different hypothesis: that tretinoin boosts the follicular enzymes needed to activate minoxidil in the first place.

How the Research Was Conducted

The investigators recruited 20 adults (10 men, 10 women, average age 32) from a hospital dermatology department in Mumbai, India. All had been diagnosed with androgenetic alopecia: the men averaged Norwood stage III, the women Ludwig stage II. No participant had used minoxidil, finasteride, or any retinoid in the previous six months.

Protocol

A 10 cm × 10 cm target area was marked on each subject’s scalp.
At baseline, 10 hairs with visible bulbs were plucked from the target area and analyzed with the Minoxidil Response Test (MRT), an in-vitro diagnostic that quantifies sulfotransferase activity. A score below 0.4 predicts non-response to minoxidil.
The investigator applied approximately 2 mg/cm² of 0.1% tretinoin cream to the target area. Subjects then continued applying the cream once daily for four more days (five applications total).
On day 6, 10 hairs were again plucked and tested. The investigator also inspected the target area for adverse reactions.

Each MRT data point represented the average of four separate measurements, adding a layer of analytical rigor. Statistical analysis used one-sided paired t-tests.

Results

All 20 subjects completed the study with no reported adverse events and no visible adverse reactions on inspection.

Whole Cohort

Mean sulfotransferase activity before treatment was 0.57 ± 0.33 and after treatment was 0.58 ± 0.29. This difference was not statistically significant (p = 0.187). In other words, across all 20 patients, tretinoin did not produce a meaningful overall shift in enzyme activity.

Predicted Non-Responders (Baseline MRT < 0.4)

Seven subjects fell below the 0.4 threshold at baseline. For this subgroup:

Pre-treatment mean: 0.26 ± 0.09
Post-treatment mean: 0.35 ± 0.16
p = 0.0397 (statistically significant)

Three of these seven subjects (43%) crossed the 0.4 threshold after five days of tretinoin, reclassifying them as predicted responders to minoxidil. The remaining four showed some increase in enzyme activity but stayed below the cutoff.

Subject-Level Data

The individual results reveal considerable variability. Some subjects who were already strong responders at baseline saw their enzyme levels drop slightly after tretinoin (for example, Subject 15 went from 0.766 to 0.365). Others saw dramatic increases (Subject 4 rose from 0.290 to 0.575; Subject 8 jumped from 0.419 to 1.042). This variability underscores that the biological response to tretinoin is not uniform.

Conclusions

The authors propose a new mechanistic explanation for the clinical synergy between tretinoin and minoxidil. Rather than simply thinning the skin barrier, tretinoin appears to upregulate the sulfotransferase enzymes that convert minoxidil into its active sulfated form. This is biologically plausible: all-trans retinoic acid is a known agonist of the RXR nuclear receptor, which participates in the regulation of sulfotransferase gene expression. Previous in-vitro work in hepatic cells demonstrated the same induction effect.

The authors also offer an elegant reinterpretation of earlier findings. Previous studies detected higher blood levels of minoxidil in patients using tretinoin and attributed it to increased skin penetration. But minoxidil sulfate is more water-soluble than minoxidil, meaning that enhanced sulfonation in the follicle could itself explain higher systemic absorption, without invoking changes in barrier function.

What the Study Does Not Prove

It does not demonstrate that tretinoin actually causes more hair to grow. The endpoint was enzyme activity, not clinical hair regrowth.
The sample size was small (20 subjects, only 7 non-responders), so the 43% conversion rate should be interpreted cautiously.
The treatment period was only five days. Whether sulfotransferase upregulation persists with ongoing tretinoin use, and whether it translates to long-term clinical benefit, remain unknown.
The study did not include a control group receiving a vehicle cream without tretinoin, which limits the ability to rule out placebo or mechanical effects of daily cream application.

Relevance to Topical Alopecia Treatments

This study has direct implications for formulating and using topical hair loss treatments. If tretinoin can genuinely boost the enzymatic machinery that activates minoxidil, then combination products containing both ingredients could help a larger proportion of patients benefit from minoxidil therapy.

Current combination topical solutions that pair minoxidil with tretinoin already exist in compounding pharmacies and some commercial formulations. This research provides a biochemical rationale for that combination that goes beyond the older skin-penetration theory. Importantly, it suggests the benefit may be greatest for patients who would otherwise not respond to minoxidil at all, a group that represents roughly 60% of users.

The concept also extends beyond tretinoin specifically. The authors note that sulfotransferase is regulated by several nuclear receptor pathways, including PXR and CAR in addition to RXR. Other compounds that activate these pathways might serve as future adjuvants. This line of research could eventually expand the toolkit of topical ingredients designed to make minoxidil work better.

A practical caution: tretinoin can cause irritation, dryness, and photosensitivity, particularly on the scalp. Any incorporation into a topical hair loss regimen should be guided by a dermatologist, and concentration and frequency need to be calibrated to individual tolerance.

Who This Study Matters Most For

Minoxidil non-responders: Individuals who have used topical minoxidil for six months or more without noticeable results may carry low follicular sulfotransferase activity. This research suggests tretinoin could potentially convert some of them into responders.
Patients considering combination topical therapies: Those exploring compounded solutions containing minoxidil and tretinoin now have a clearer understanding of why the combination might help.
Clinicians and formulators: This study provides mechanistic evidence that may guide the development of next-generation topical treatments for androgenetic alopecia.
Women with pattern hair loss: Half the study cohort was female, and the results apply equally. Given that women have fewer FDA-approved options, combination strategies are especially relevant.

Sources and Citations

Primary Study

Sharma, A., Goren, A., Dhurat, R., Agrawal, S., Sinclair, R., Trüeb, R. M., Vañó-Galván, S., Chen, G., Tan, Y., Kovacevic, M., Situm, M. & McCoy, J. Tretinoin enhances minoxidil response in androgenetic alopecia patients by upregulating follicular sulfotransferase enzymes. Dermatologic Therapy, e12915. https://doi.org/10.1111/dth.12915

Selected References Cited by the Authors

Olsen, E.A. et al. (2007). A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo. Journal of the American Academy of Dermatology, 57, 767–774.
Buhl, A.E. et al. (1990). Minoxidil sulfate is the active metabolite that stimulates hair follicles. Journal of Investigative Dermatology, 95, 553–577.
Goren, A. et al. (2015). Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Dermatologic Therapy, 28, 13–16.
Bazzano, G.S. et al. (1986). Topical tretinoin for hair growth promotion. Journal of the American Academy of Dermatology, 15, 880–883.
Kwon, O.S. et al. (2007). Promotive effect of minoxidil combined with all-trans retinoic acid on human hair growth in vitro. Journal of Korean Medical Science, 22, 283–289.
Ferry, J.J. et al. (1990). Influence of tretinoin on the percutaneous absorption of minoxidil from an aqueous topical solution. Clinical Pharmacology & Therapeutics, 47, 439–446.
Maiti, S., Chen, X., Chen, G. (2005). All-trans retinoic acid induction of sulfotransferases. Basic & Clinical Pharmacology & Toxicology, 96, 44–53.
Kodama, S., Negishi, M. (2013). Sulfotransferase genes: regulation by nuclear receptors in response to xeno/endo-biotics. Drug Metabolism Reviews, 45, 441–449.